Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe Registry

0585914 - ÚI 2025 RIV US J - Článek v odborném periodiku
Gwechenberger, M. - Barón-Esquivias, G. - De Vries, T. A. C. - Siller-Matula, J. M. - Manu, M. C. - Souza, J. - Wienerroither, S. - Pecen, Ladislav - De Groot J. R. - De Caterina, R. - Kirchhof, P.
Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe Registry.
JACC Advances. Roč. 3, č. 4 (2024), č. článku 100880. ISSN 2772-963X
Institucionální podpora: RVO:67985807
Klíčová slova: atrial fibrillation * direct acting oral anticoagulant * edoxaban * ETNA-AF-Europe * worsening renal function
Obor OECD: Cardiac and Cardiovascular systems
Způsob publikování: Open access

BACKGROUND: Managing patients with atrial fibrillation (AF) and worsening renal function (WRF) remains a clinical challenge due to the need of dose adjustment of non-vitamin K antagonist oral anticoagulants. Objectives: To determine the incidence of WRF in patients with AF treated with edoxaban, the association of WRF with clinical outcomes, and predictors of WRF and clinical outcomes in these patients. METHODS: This is a subanalysis of the Edoxaban Treatment in routine clinical practice for patients with non-valvular Atrial Fibrillation in Europe study (NCT02944019), an observational study of edoxaban-treated patients with AF. WRF was defined as a ≥25% reduction in creatinine clearance between baseline and 2 years. RESULTS: Of the 9,054 patients included (69% of the total 13,133 enrolled), most did not experience WRF (90.3%) during the first 2 years of follow-up. WRF occurred in 9.7% of patients. Patients with WRF had significantly higher rates of all-cause death (3.88%/y vs 1.88%/y, P < 0.0001), cardiovascular death (2.09%/y vs 0.92%/y, P < 0.0001), and major bleeding (1.51%/y vs 0.98%/y, P = 0.0463) compared with those without WRF. Rates of intracranial hemorrhage (0.18%/y vs 0.18%/y) and of any stroke/systemic embolic events were low (0.90%/y vs 0.69%/y, P = 0.3161) in both subgroups. The strongest predictors of WRF were a high CHA2DS2-VASc score, high baseline creatinine clearance, low body weight, and older age. Most predictors of WRF were also predictors of clinical outcomes. CONCLUSIONS: WRF occurred in approximately 10% of edoxaban-treated AF patients. Rates of death and major bleeding were significantly higher in patients with WRF than without. Stroke events were low in both subgroups.
Trvalý link: https://hdl.handle.net/11104/0353553